Dr. Reddy's launches over-the-counter store brand equivalent of Prilosec OTC® (Omeprazole Delayed-Release) Tablets, 20 mg in the U.S. Market

Deepthi | Myequity news | Date : 11-12-2018 11:11:00 IST

Dr. Reddy's Laboratories Ltd. launched Omeprazole Delayed-Release Tablets, 20 mg, an over-the-counter (OTC) store-brand equivalent of Prilosec® OTC (omeprazole delayed-release) Tablets, 20 mg, in the United States market as approved by the U.S. Food and Drug Administration (USFDA).

OTC Omeprazole Delayed-Release Tablets, 20 mg, is a proton pump inhibitor used to treat frequent heartburn occurring two or more days per week in adults.

"This launch illustrates our continued commitment to the OTC business as well as the depth and breadth of our OTC portfolio," says Milan Kalawadia, Vice President and Head, US OTC and Speciality Rx businesses, Dr. Reddy's Laboratories. "We look forward to collaborating with our customers to provide high-quality, affordable alternatives to consumers."


The combined market of Prilosec OTC® and private label omeprazole OTC products had U.S. retail sales of approximately $492 million for the most recent twelve months ending in October 2018 according to IRI+.

About Dr. Reddy's:

Dr. Reddy's Laboratories Ltd. is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.


More from Myequity